This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Siegel, J N Search for Related Content PubMed PubMed Citation Articles by Siegel, J N Social Bookmarking                   What's this?

Development of an FDA guidance document for clinical trials in SLE

Division of Clinical Trials Design and Analysis, OTRR, CBFR, Food and Drug Administration, Rockville MD, USA

To make the process of developing new therapeutic agents more efficient, it is critical that investigators and industry sponsors understand in advance what information they will need to provide to the US Food and Drug Administration (FDA) in order to license and market their product. To facilitate that process, the FDA publishes guidance documents describing current thinking about various issues that arise at all stages of product development. The FDA is currently in the process of formulating a guidance document about clinical development programs for systemic lupus erythematosus (SLE). The goal of this document is to describe some of the types of clinical trials that could be used to demonstrate safety and efficacy of therapeutic agents in SLE.

Key Words: clinical trials • disease activity • lupus nephritis

Lupus, Vol. 8, No. 8, 581-585 (1999)
DOI: 10.1191/096120399680411425


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?